Teva to Resume Production of Vincristine After Widespread Shortages
With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.
Teva announced it will resume manufacturing vincristine, a widely-used chemotherapy agent, following its previous decision to discontinue production, the company announced on Wednesday.
In a
Vincristine is used to treat several types of blood cancers, including acute lymphoblastic leukemia, one of the most common childhood cancers.
In response to the shortage, 1 circulating
Generic injectable drugs are most vulnerable to shortages, mostly due to fewer suppliers, long lead times, and manufacturing complexity, according to the FDA.3 The agency recently released a report highlighting
According to the Twitter post, when Teva removed vincristine from the market, “the company was only supplying 3% of the market and, without any information to the contrary, anticipated that that volume could quickly and easily be absorbed by the brand manufacturer, which was supplying the other 97%.”
Now, Teva has decided to re-introduce the product and plans to manufacture it in its US plant, “which provides the fastest route to market.”
In October, the
In the meantime, providers can follow several recommendations to help prepare and plan for a shortage crisis. In addition, pharmacists can stay updated on drug shortages by regularly visiting ASHP (
References
- Pfizer Inc. Supply Update Notification for Vincristine Sulfate Injection, USP Presentations. FDA’s website. October 18, 2019. https://www.fda.gov/media/131865/download. Accessed November 14, 2019.
- Robin RC. Faced With a Drug Shortfall, Doctors Scramble to Treat Children With Cancer. The New York Times. October 14, 2019. https://www.nytimes.com/2019/10/14/health/cancer-drug-shortage.html.
- FDA. Drug Shortages: Root Causes and Potential Solutions. 2019. FDA’s website. https://www.fda.gov/media/132058/download. Accessed October 21, 2019.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025